Protara Therapeutics (TARA) Current Leases (2019 - 2026)

Protara Therapeutics (TARA) has 8 years of Current Leases data on file, last reported at $1.3 million in Q1 2026.

• On a quarterly basis, Current Leases rose 8.03% year-over-year to $1.3 million in Q1 2026; TTM through Mar 2026 was $1.3 million, a 8.03% increase from a year earlier, with the FY2025 full-year figure at $1.2 million, up 10.5% from the prior year.
• Current Leases for Q1 2026 stood at $1.3 million, up from $1.2 million in the prior quarter.
• Over the last five years, Current Leases for TARA reached as high as $1.3 million in Q1 2026 and fell as low as $870000.0 in Q1 2022.
• Historically, Current Leases has averaged $1.0 million across 5 years, with a median of $1.0 million in 2024.
• On a YoY basis, Current Leases climbed as much as 845.65% in 2022 and fell as far as 7.14% in 2022.
• Year by year, Current Leases stood at $917000.0 in 2022, then rose by 7.2% to $983000.0 in 2023, then gained by 14.34% to $1.1 million in 2024, then advanced by 10.5% to $1.2 million in 2025, then rose by 1.77% to $1.3 million in 2026.
• Per Business Quant data, the three most recent Current Leases figures were $1.3 million in Q1 2026, $1.2 million in Q4 2025, and $1.2 million in Q3 2025.